Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tranexamic Acid

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Lysteda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Amring Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition December 02, 2020

            Details:

            Acquisition of the global rights to LYSTEDA® (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB), will further strengthen Amring's position in the marketplace.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Menotropins

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Menopur

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 15, 2020

            Details:

            Abstract titled "Differential Ovarian Response to Gonadotropin Preparations Despite Similar Ovarian Reserve: MENOPUR in GnRH (Gonadotropin Releasing Hormone) Antagonist Single Embryo Transfer – High Responder (MEGASET-HR) Trial Analysis" will be presented at the conference.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Carbetocin

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            Carbetocin Ferring is the first medicine approved under the new Swissmedic and Marketing Authorisation for Global Health Products (MAGHP) procedure, which aims to build capacity and speed up access to essential medicines in low- and middle-income countries.